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Clinical PerspectiveWhat Is New?Atrial fibrillation (AF) catheter ablation improved renal function over the 5‐year follow‐up, whereas medical therapy did not.No recurrence after the last AF ablation procedure was independently associated with an improved long‐term renal function~,~ especially in patients without diabetes mellitus.Impaired renal function was associated with an atrial structural remodeling in AF patients, but did not affect the rhythm outcome of AF catheter ablation.What Are the Clinical Implications?AF catheter ablation and reduction of AF burden can improve renal function over a long‐term period, especially in patients without diabetes mellitus.

Introduction {#jah34342-sec-0008}
============

Atrial fibrillation (AF), a common arrhythmia that increases mortality by 2 to 3 times,[1](#jah34342-bib-0001){ref-type="ref"} is a progressive degenerative disease[2](#jah34342-bib-0002){ref-type="ref"} associated with strokes,[1](#jah34342-bib-0001){ref-type="ref"} dementia,[1](#jah34342-bib-0001){ref-type="ref"} and heart failure.[1](#jah34342-bib-0001){ref-type="ref"} Chronic kidney disease (CKD) has a well‐established association with cardiovascular disease, and all‐cause mortality and cardiovascular mortality progressively increase as renal function declines.[3](#jah34342-bib-0003){ref-type="ref"}, [4](#jah34342-bib-0004){ref-type="ref"} It has been shown that 7% to 18% of patients with a CKD stage of ≥3 (estimated glomerular filtration rate \[eGFR\] \<60 mL/min/1.73 m^2^) have concomitant AF, and 10% to 15% of AF patients have CKD.[5](#jah34342-bib-0005){ref-type="ref"}, [6](#jah34342-bib-0006){ref-type="ref"}, [7](#jah34342-bib-0007){ref-type="ref"} This relationship becomes more significant for those aged \>70 years. Patients with both AF and CKD have an increased risk of bleeding and thromboembolisms.[7](#jah34342-bib-0007){ref-type="ref"} Washam et al[8](#jah34342-bib-0008){ref-type="ref"} reported that AF rhythm control by antiarrhythmic drugs did not affect all‐cause mortality and risk of a stroke in patients in the ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry data. In contrast, AF catheter ablation has been known to be a more‐effective method of AF rhythm control than antiarrhythmic drugs,[9](#jah34342-bib-0009){ref-type="ref"} and it is known to lower the heart failure mortality[10](#jah34342-bib-0010){ref-type="ref"}, [11](#jah34342-bib-0011){ref-type="ref"} and risk of cerebral infarctions[12](#jah34342-bib-0012){ref-type="ref"} and improve the cognitive function.[13](#jah34342-bib-0013){ref-type="ref"}, [14](#jah34342-bib-0014){ref-type="ref"} However, studies on renal‐function changes after AF rhythm control by catheter ablation have been limited thus far. Takahashi et al reported that maintenance of sinus rhythm after a single AF catheter ablation resulted in a positive effect on renal function.[15](#jah34342-bib-0015){ref-type="ref"} After a successful AF ablation, left ventricular systolic function improves and mean heart rate increases because of autonomic nerve modulation.[16](#jah34342-bib-0016){ref-type="ref"}, [17](#jah34342-bib-0017){ref-type="ref"} As a result, cardiac output increases, and a positive effect on renal function is expected after a successful AF ablation. However, given that AF has a substantial long‐term recurrence rate after catheter ablation, there are no data on changes in renal function over a 5‐year long‐term period or after repeated procedures. Therefore, we hypothesized that an optimal AF rhythm control, including a repeat ablation, may improve long‐term renal function beyond 5 years. In this study, we compared the change in renal function in AF patients who underwent catheter ablation followed by a guideline‐based regular rhythm follow‐up (Yonsei AF ablation cohort) and those that underwent medical therapy alone (Korean National Health Insurance \[NHIS\] database) over a peirod of 5 years. We also explored the relationship of the change in long‐term renal function after AF catheter ablation to rhythm outcome or degree of atrial remodeling.

Methods {#jah34342-sec-0009}
=======

The data, analytic methods, and study materials that support the findings of this study are available from the corresponding author upon reasonable request.

Study Population {#jah34342-sec-0010}
----------------

This study protocol adhered to the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the Yonsei University Health System. The medical therapy group was selected from the NHIS database (NHIS‐2018‐2‐189), and the ablation therapy group was selected from the Yonsei AF Ablation cohort (registered at ClinicalTrials.gov Identifier: NCT02138695). Both groups were enrolled as nonvalvular AF patients with baseline and 5‐year follow‐up eGFR (estimated by Chronic Kidney Disease Epidemiology Collaboration \[CKD‐EPI\] equation) data. In the AF ablation group, all patients provided written informed consent for inclusion in the Yonsei AF Ablation study. The informed consent requirement in the medical therapy group from the NHIS database was waived. Among 1963 patients who underwent AF catheter ablation (AFCA) for symptomatic drug‐refractory AF, 571 patients (59±10 years, 72.3% male, and 66.5% paroxysmal AF) who had 5‐year serial eGFR data after AF ablation were enrolled in this study. All patients stopped their antiarrhythmic drugs for a period of time corresponding to at least 5 half‐lives before catheter ablation. During the 5‐year follow‐up period, 103 patients underwent a second ablation, and 3 underwent a third ablation for antiarrhythmic‐resistant recurrent AF (Figure [1](#jah34342-fig-0001){ref-type="fig"}). In the medical therapy group, among 14 056 patients with nonvalvular AF who were not treated with catheter ablation in the NHIS database, 1713 patients (59±11 years, 73.2% male) who had both baseline and 5‐year follow‐up renal function data were enrolled in this study for the control group after propensity‐score matching with the AF ablation group. Exclusion criteria were as follows: (1) permanent AF refractory to electrical cardioversion, (2) AF with rheumatic valvular disease, and (3) previous cardiac surgery with concomitant AF surgery or AF catheter ablation.

![Study flow chart of the patient enrollment. ACEi indicates angiotensin‐converting‐enzyme inhibitor; AF, atrial fibrillation; AFCA,AF catheter ablation; ARB, angiotensin type II receptor blocker; eGFR, estimated glomerular filtration rate.](JAH3-8-e013204-g001){#jah34342-fig-0001}

Electrophysiological Mapping and Radiofrequency Catheter Ablation {#jah34342-sec-0011}
-----------------------------------------------------------------

3D electroanatomical mapping (NavX; St. Jude Medical, Inc, Minnetonka, MN) was generated using a circumferential pulmonary vein (PV)‐mapping catheter (Lasso; Biosense‐Webster Inc, Diamond Bar, CA) through a long sheath (Schwartz left 1; St. Jude Medical, Inc). Multiview pulmonary venograms were obtained after the trans‐septal punctures. The 3D geometry of both the left atrium (LA) and PVs was generated using the NavX system and then merged with 3D spiral computed tomography images. Systemic anticoagulation with intravenous heparin was achieved to maintain an activated clotting time of 350 to 400 seconds during the procedure.

An open‐irrigated tip catheter (Celsius; Johnson & Johnson Inc, Diamond Bar, CA; NaviStar ThermoCool, Biosense Webster Inc; ThermoCool SF, Biosense Webster Inc; ThermoCool SmartTouch, Biosense Webster Inc; Coolflex, St. Jude Medical Inc; 30--35 W; 47°C; FlexAbility, St Jude Medical Inc; ThermoCool SmartTouch, Biosense Webster Inc, and TactiCath, St. Jude Medical Inc) was used for AFCA. All patients underwent a de novo procedure with a circumferential pulmonary vein isolation. The majority of the patients (94.2%) underwent a cavotricuspid isthmus block during the de novo procedure if there was no atrioventricular conduction disease. We conducted an additional linear ablation including a roof line, posterior inferior line (posterior box lesion), and anterior line, especially in patients with persistent AF. A left lateral isthmus ablation, right atrial ablation, and complex fractionated electrogram ablation were performed in a minority of the patients at the operator\'s discretion. The de novo procedure ended when there was no immediate recurrence of AF within 10 minutes after the cardioversion with an isoproterenol infusion (5--10 μg/min). In the case of mappable AF triggers or premature atrial beats, non‐PV foci were carefully mapped and ablated as much as possible.

The detailed technique and strategy for the repeat ablation procedures were presented in a previous study.[18](#jah34342-bib-0018){ref-type="ref"} If there were reconnections of PV potentials or a previous linear ablation, we completed the circumferential pulmonary vein isolation and accomplished bidirectional block of the circumferential pulmonary vein isolation, cavotricuspid isthmus, or linear ablation as much as possible. Then, we provoked extra‐PV foci with an isoproterenol infusion (5--10 μg/min) and carefully mapped and ablated mappable AF triggers or frequent atrial premature beats. If there were multiple extra‐PV triggers, we conducted an additional linear ablation or an electrogram‐guided ablation at the operators' discretion.

Postablation Management and Follow‐up {#jah34342-sec-0012}
-------------------------------------

Patients visited the outpatient clinic at 1, 3, 6, and 12 months and every 6 months thereafter or whenever symptoms developed after the AFCA. ECG was performed at every visit. Twenty‐four‐hour Holter monitoring was performed at 3, 6, and 12 months and then every 6 months after the AFCA according to the 2012 Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society expert consensus statement guidelines.[19](#jah34342-bib-0019){ref-type="ref"} Patients underwent an annual laboratory examination (serum creatinine, blood urea nitrogen, urine hemoglobin, and dipstick urine protein). eGFR was estimated by the CKD‐EPI equation. Patients who suffered from symptoms of palpitations underwent Holter/event‐monitor examinations to investigate the possibility of an arrhythmia recurrence. We defined an AF recurrence as any episode of atrial tachycardia (AT) or AF lasting for 30 seconds or more. Any ECG documentation of an AF recurrence after a 3‐month blanking period was classified as a clinical recurrence.

Statistical Analysis {#jah34342-sec-0013}
--------------------

Continuous variables are expressed as mean±SD and were analyzed using a Student *t* test. Categorical variables are reported as numbers (percentages) and were analyzed using a chi‐square or Fisher\'s exact test. We used a paired *t* test to investigate changes in eGFR~5 yr~ (ΔeGFR~5 yr~) in both the AFCA group and control group. Also, we compared ΔeGFR~5 yr~ after AFCA according to freedom from AF/AT recurrence by using a paired *t* test. A multivariate logistic regression analysis was used to investigate whether AF catheter ablation improved renal function and identify predictors associated with an improvement in renal function in patients who underwent AF catheter ablation. The variables with a *P* value under 0.05 were included in the multivariate model. Furthermore, we did not use a step‐wise selection model in multivariate regression analysis. A Kaplan--Meier analysis was used to analyze probability of freedom from AF/AT recurrence after AFCA according to a concomitant impaired renal function. Propensity matching was performed without a replacement and with a caliper of 0.01 at a 1: 3 ratio of the AF ablation group and medical therapy group based on the following variables: age, sex, body mass index, congestive heart failure, hypertension, diabetes mellitus, previous history of a stroke or transient ischemic attack, previous history of vascular disease, CHA~2~DS~2~VASc score, baseline eGFR, and medications, including angiotensin‐converting enzyme inhibitors, angiotensin type II receptor blockers, β‐blockers, and statins. *P*\<0.05 was considered statistically significant. All statistical analyses were performed using SPSS (version 23.0; SPSS, Inc, Chicago, IL) software for Windows.

Results {#jah34342-sec-0014}
=======

AF Catheter Ablation Versus Medical Therapy {#jah34342-sec-0015}
-------------------------------------------

Baseline characteristics in the AF catheter ablation group and propensity‐score--matched control group are presented in Table [1](#jah34342-tbl-0001){ref-type="table"}. There were no significant differences in patient characteristics, medication use, and baseline eGFR between the AFCA group and medical therapy group. Nonetheless, eGFR measured at the 5‐year follow‐up in patients who underwent AFCA was significantly higher than that in patients with medical therapy (84.6±19.4 versus 82.4±18.1 mL/min/1.73 m^2^; *P*=0.014; Figure [2](#jah34342-fig-0002){ref-type="fig"}A). ΔeGFR~5 yr~ was also significantly higher in patients with AFCA as compared with patients with medical therapy (3.2±13.6 versus 0.7±16.8 mL/min/1.73 m^2^; *P*\<0.001; Figure [2](#jah34342-fig-0002){ref-type="fig"}B). Among the overall 2284 patients, a young age (adjusted odds ratio \[OR\], 0.98 \[0.97--0.99\]; *P*\<0.001; Table [2](#jah34342-tbl-0002){ref-type="table"}) and AF catheter ablation (adjusted OR, 2.02 \[1.67--2.46\]; *P*\<0.001; Table [2](#jah34342-tbl-0002){ref-type="table"}) were independently associated with an improved renal function (ΔeGFR~5 yr~, \>0 mL/min/1.73 m^2^) after the 5‐year follow‐up after when adjusting for preexisting hypertension and angiotensin‐converting enzyme inhibitor/angiotensin type II receptor blocker use. We tested the different thresholds of ΔeGFR~5 yr~ based on previous studies,[15](#jah34342-bib-0015){ref-type="ref"}, [20](#jah34342-bib-0020){ref-type="ref"}, [21](#jah34342-bib-0021){ref-type="ref"}, [22](#jah34342-bib-0022){ref-type="ref"} and found that AFCA was a consistent variable of long‐term improvement in renal function (Tables [S1 through S3](#jah34342-sup-0001){ref-type="supplementary-material"}).

###### 

Comparison of the Baseline Characteristics and eGFR in AF Patients With AFCA or Medical Therapy

                          Overall        AFCA          Medical therapy   *P* Value   ASMD
  ----------------------- -------------- ------------- ----------------- ----------- -------
  Age, y                  59±10          59±10         59±11.0           0.895       0.006
  Male                    1667 (73%)     413 (72.3%)   1254 (73.2%)      0.683       0.020
  Body mass index         24.8±3.0       24.9±2.8      24.8±3.0          0.312       0.046
  CHA~2~DS~2~VASc score   1.7±1.5        1.8±1.5       1.7±1.6           0.546       0.029
  CHF                     110 (4.8%)     30 (5.3%)     80 (4.7%)         0.573       0.027
  Hypertension            1163 (50.9%)   290 (50.8%)   873 (51%)         0.942       0.004
  Diabetes mellitus       394 (17.3%)    99 (17.3%)    295 (17.2%)       0.949       0.003
  Stroke/TIA              263 (11.5%)    67 (11.7%)    196 (11.4%)       0.850       0.009
  Vascular disease        336 (14.7%)    92 (16.1%)    244 (14.2%)       0.275       0.052
  ACEi/ARB use            862 (37.8%)    206 (36.1%)   656 (38.3%)       0.358       0.046
  Beta‐blocker use        676 (29.6%)    160 (28.1%)   516 (30.1%)       0.353       0.046
  Statin use              653 (28.6%)    160 (28.1%)   493 (28.8%)       0.745       0.017
  Baseline eGFR           81.7±16.9      81.4±18.5     81.8±16.3         0.685       0.02

The patients under medical therapy were included in this study after propensity‐score matching for the age, sex, body mass index, CHF, hypertension, diabetes mellitus, stroke/TIA, vascular disease, CHA~2~DS~2~VASc score, baseline eGFR, ACEi/ARB use, beta‐blocker use, and statin use. ACEi indicates angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; AFCA, AF catheter ablation; ARB, angiotensin type II receptor blocker; ASMD, absolute standardized mean differences; CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; TIA, transient ischemic attack.

![Mean estimated glomerular filtration rate (eGFR) measured at baseline and 5 years of follow‐up between the AFCA and medication groups (**A**). Comparison of the increase in the eGFR from baseline to 5 years (▵eGFR ~5 yrs~) between the AFCA and medication groups (**B**). AFCA indicates atrial fibrillation catheter ablation.](JAH3-8-e013204-g002){#jah34342-fig-0002}

###### 

Logistic Regression Analysis for Variables Predicting an Improved Renal Function (ΔeGFR~5 yr~ \>0) After 5 Years of Follow‐up (n=2284)

                          Univariate             Multivariate Model                                                      
  ----------------------- ---------------------- ------------------------------------------------ ---------------------- ------------------------------------------------
  Age                     0.980 (0.972--0.987)   \<0.001[a](#jah34342-note-0005){ref-type="fn"}   0.980 (0.972--0.989)   \<0.001[a](#jah34342-note-0005){ref-type="fn"}
  Male                    0.915 (0.761--1.101)   0.347                                                                   
  Body mass index         1.015 (0.988--1.044)   0.279                                                                   
  CHA~2~DS~2~VASc score   0.946 (0.897--0.999)   0.044[a](#jah34342-note-0005){ref-type="fn"}                            
  CHF                     0.746 (0.505--1.102)   0.141                                                                   
  Hypertension            0.840 (0.712--0.990)   0.037[a](#jah34342-note-0005){ref-type="fn"}     1.005 (0.826--1.222)   0.961
  Diabetes mellitus       0.888 (0.714--1.105)   0.288                                                                   
  Stroke/TIA              0.914 (0.706--1.183)   0.494                                                                   
  Vascular disease        1.037 (0.822--1.308)   0.759                                                                   
  ACEi/ARB use            0.801 (0.675--0.949)   0.010[a](#jah34342-note-0005){ref-type="fn"}     0.871 (0.715--1.060)   0.169
  BB use                  0.855 (0.714--1.024)   0.089                                                                   
  Statin use              0.985 (0.821--1.181)   0.870                                                                   
  AFCA                    2.021 (1.666--2.450)   \<0.001[a](#jah34342-note-0005){ref-type="fn"}   2.023 (1.666--2.457)   \<0.001[a](#jah34342-note-0005){ref-type="fn"}

The CHA~2~DS~2~VASC score was not included in multivariate model in Table [2](#jah34342-tbl-0002){ref-type="table"} because the age and hypertension variables had already been considered to calculate the CHA~2~DS~2~VASc score. ACEi indicates angiotensin‐converting enzyme inhibitor; AFCA, atrial fibrillation catheter ablation; ARB, angiotensin type II receptor blocker; BB, beta blocker; CHF, congestive heart failure; OR, odds radio; TIA, transient ischemic attack.

Statistical significance.

Patient Characteristics With a Renal Function Improvement After AFCA {#jah34342-sec-0016}
--------------------------------------------------------------------

Table [3](#jah34342-tbl-0003){ref-type="table"} summarizes the comparison of baseline characteristics, including echocardiographic parameters and clinical rhythm outcome of 571 patients according to improvement in renal function (ΔeGFR~5 yr~, \>0 mL/min/1.73 m^2^). Patients whose renal function improved during the 5‐year follow‐up were younger (*P*=0.008), had a lower CHA~2~DS~2~VASc score (*P*=0.015) and lower hypertension (*P*=0.003), took less angiotensin‐converting enzyme inhibitors/angiotensin type II receptor blockers after the de novo ablation procedure (*P*=0.046), and were more likely to maintain sinus rhythm after the last ablation procedure (*P*=0.036) than those without renal function improvement.

###### 

Comparison of the Baseline Characteristics, Catheter Ablation, and Clinical Rhythm Outcomes According to an Improved Renal Function (ΔeGFR~5 yr~ \>0) Among the Overall Patients With AFCA (n=571)

                                                  Overall Patients With AFCA   Improved Renal Function   Nonimproved Renal Function   *P* Value
  ----------------------------------------------- ---------------------------- ------------------------- ---------------------------- ----------------------------------------------
  Age, y                                          59±10                        58±10                     60±10                        0.008[a](#jah34342-note-0007){ref-type="fn"}
  Male                                            413 (72.3%)                  245 (71.6%)               168 (73.4%)                  0.652
  PAF at procedure                                380 (66.5%)                  231 (67.5%)               149 (65.1%)                  0.538
  Body mass index                                 24.9±2.8                     24.9±2.9                  24.9±2.8                     0.850
  Body surface area                               1.80±0.17                    1.81±0.18                 1.80±0.17                    0.445
  CHA~2~DS~2~VASc score                           1.8±1.5                      1.7±1.5                   2.0±1.5                      0.015[a](#jah34342-note-0007){ref-type="fn"}
  Congestive heart failure                        30 (5.3%)                    13 (3.8%)                 17 (7.4%)                    0.057
  Hypertension                                    290 (50.8%)                  156 (45.6%)               134 (58.5%)                  0.003[a](#jah34342-note-0007){ref-type="fn"}
  Diabetes mellitus                               99 (17.3%)                   56 (16.4%)                43 (18.8%)                   0.457
  Stroke/TIA                                      67 (11.7%)                   38 (11.1%)                29 (12.7%)                   0.572
  Vascular disease                                92 (16.1%)                   55 (16.1%)                37 (16.2%)                   0.981
  LA dimension, mm                                41.9±6.1                     41.9±6.1                  41.9±6.1                     0.911
  LVEF, %                                         63.4±8.0                     63.3±7.6                  63.5±8.7                     0.785
  E/Em                                            10.6±5.0                     10.6±5.3                  10.6±4.5                     0.999
  Postablation ACEi/ARB use                       206 (36.1%)                  112 (32.8%)               94 (41.0%)                   0.046[a](#jah34342-note-0007){ref-type="fn"}
  Postablation BB use                             160 (28.1%)                  89 (26.1%)                71 (31%)                     0.201
  Postablation Statin use                         160 (28.1%)                  96 (28.2%)                64 (27.9%)                   0.957
  Postablation AAD use                            128 (22.4%)                  68 (19.9%)                60 (26.2%)                   0.076
  Advanced CKD at baseline                        67 (11.7%)                   33 (9.6%)                 34 (14.8%)                   0.059
  Repeat ablations                                106 (18.6%)                  70 (20.5%)                36 (15.7%)                   0.153
  Freedom from AF/AT recurrence after last AFCA   366 (64.1%)                  231 (67.5%)               135 (59%)                    0.036[a](#jah34342-note-0007){ref-type="fn"}

ΔeGFR~5 yr~ indicates the increase in the eGFR from baseline to 5 years after the AF ablation; AAD, antiarrhythmic drugs; ACEi, angiotensin‐converting‐enzyme inhibitor; AF, atrial fibrillation; AFCA, atrial fibrillation catheter ablation; ARB, angiotensin type II receptor blocker; AT, atrial tachycardia; BB, beta blocker; CKD, chronic kidney disease; E/Em, the ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity (Em); eGFR, estimated glomerular filtration rate; LA, left atrium; LVEF, left ventricular ejection fraction; PAF, paroxysmal atrial fibrillation; TIA, transient ischemic attack.

Statistical significance.

Factors Associated With Improvement in Renal Function in Patients That Underwent AFCA {#jah34342-sec-0017}
-------------------------------------------------------------------------------------

Among the overall 571 patients, 465 underwent a single ablation procedure and the others underwent multiple procedures during the follow‐up period. In the patients with a single procedure alone, 64.1% (298 of 465) were free from an AF/AT recurrence, and in the overall patients with single or multiple procedures, 64.1% (366/571) were free from an AF/AT recurrence after the last ablation procedure during the 5‐year follow‐up period. Mean follow‐up duration after the last ablation session in the 571 overall patients was 42.4±21.3 months, and in the 106 patients who underwent multiple procedures was 27.8±18.0 months. The 5‐year follow‐up eGFR was significantly higher than baseline eGFR in the patients without an AF/AT recurrence in both the overall ablation group (82.1±17.8--86.2±18.8 mL/min/1.73 m^2^; *P*\<0.001; Figure [3](#jah34342-fig-0003){ref-type="fig"}A) and single‐procedure group (81.4±17.9--85.2±19.4 mL/min/1.73 m^2^; *P*\<0.001; Figure [3](#jah34342-fig-0003){ref-type="fig"}D). However, there was no significant improvement in 5‐year follow‐up eGFR in patients with an AF/AT recurrence (Figure [3](#jah34342-fig-0003){ref-type="fig"}B and [3](#jah34342-fig-0003){ref-type="fig"}E). Degree of eGFR increase (ΔeGFR~5 yrs~) was significantly greater in patients who remained in sinus rhythm than in those with an AF/AT recurrence after the last ablation procedure (4.1±13.6 versus 1.5±13.4 mL/min/1.73 m^2^; *P*=0.029; Figure [3](#jah34342-fig-0003){ref-type="fig"}C). After adjusting for the CHA~2~DS~2~VASc score and postablation angiotensin‐converting enzyme inhibitor/angiotensin type II receptor blocker use, a multivariate logistic regression analysis demonstrated that freedom from an AF/AT recurrence after the last ablation procedure was independently associated with an improvement in renal function (adjusted OR, 1.44 \[1.01--2.04\]; *P*=0.043; Table [4](#jah34342-tbl-0004){ref-type="table"}).

![Scatter plot and mean changes in the estimated glomerular filtration rate (eGFR) from baseline to 5 years after AF ablation in the overall patients without an AF/AT recurrence (**A**) and those with an AF/AT recurrence (**B**), and in the single procedure alone group without an AF/AT recurrence (**D**) and those with an AF/AT recurrence (**E**). Comparison of the increase in the eGFR from baseline to 5 years (▵eGFR ~5 yrs~) according to AF/AT recurrence after the AF ablation among the patients with repeat procedures (**C**) and a single procedure alone (**F**). ACEi indicates angiotensin‐converting‐enzyme inhibitor; AF, atrial fibrillation; AFCA,AF catheter ablation; AT, atrial tachycardia.](JAH3-8-e013204-g003){#jah34342-fig-0003}

###### 

Logistic Regression Analysis of the Variables Predicting an Improved Renal Function (ΔeGFR~5 yr~ \>0) After 5 Years of Follow‐up Among the Overall Patients With AFCA (n=571)

                                                  Univariate             Multivariate Model 1                           Multivariate Model 2                                  
  ----------------------------------------------- ---------------------- ---------------------------------------------- ---------------------- ------- ---------------------- ----------------------------------------------
  Age                                             0.977 (0.961--0.994)   0.008[a](#jah34342-note-0009){ref-type="fn"}   0.984 (0.966--1.001)   0.066                          
  Male                                            0.917 (0.630--1.335)   0.652                                                                                                
  PAF at procedure                                1.117 (0.785--1.591)   0.539                                                                                                
  Body mass index                                 1.006 (0.948--1.067)   0.850                                                                                                
  Body surface area                               1.462 (0.553--3.862)   0.444                                                                                                
  CHA~2~DS~2~VASc score                           0.873 (0.781--0.975)   0.016[a](#jah34342-note-0009){ref-type="fn"}                                  0.898 (0.796--1.015)   0.084
  Congestive heart failure                        0.493 (0.235--1.035)   0.062                                                                                                
  Hypertension                                    0.595 (0.424--0.834)   0.003[a](#jah34342-note-0009){ref-type="fn"}   0.665 (0.421--1.050)   0.080                          
  Diabetes mellitus                               0.847 (0.546--1.313)   0.458                                                                                                
  Stroke/TIA                                      0.862 (0.515--1.443)   0.572                                                                                                
  Vascular disease                                0.994 (0.631--1.567)   0.981                                                                                                
  LA dimension                                    0.998 (0.971--1.026)   0.910                                                                                                
  LVEF                                            0.997 (0.976--1.018)   0.784                                                                                                
  E/Em                                            1.000 (0.966--1.035)   0.999                                                                                                
  Postablation ACEi/ARB use                       0.702 (0.496--0.994)   0.046[a](#jah34342-note-0009){ref-type="fn"}   0.991 (0.626--1.569)   0.970   0.817 (0.558--1.196)   0.298
  Postablation BB use                             0.786 (0.543--1.138)   0.202                                                                                                
  Postablation stain use                          1.010 (0.696--1.467)   0.957                                                                                                
  Postablation AAD use                            0.699 (0.470--1.039)   0.077                                                                                                
  Advanced CKD at baseline                        0.613 (0.367--1.021)   0.060                                                                                                
  Repeat ablations                                1.380 (0.887--2.147)   0.154                                                                                                
  Freedom from AF/AT recurrence after last AFCA   1.449 (1.024--2.051)   0.036[a](#jah34342-note-0009){ref-type="fn"}   1.408 (0.990--2.002)   0.057   1.436 (1.012--2.037)   0.043[a](#jah34342-note-0009){ref-type="fn"}

ΔeGFR~5 yr~ indicates the increase in the eGFR from baseline to 5 years after AF ablation; AAD, antiarrhythmic drugs; ACEi, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; AFCA, atrial fibrillation catheter ablation; ARB, angiotensin type II receptor blocker; AT, atrial tachycardia; BB, beta blocker; CKD, chronic kidney disease; E/Em, the ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity (Em); LA, left atrium; LVEF, left ventricular ejection fraction; OR, odds radio; PAF, paroxysmal atrial fibrillation; TIA, transient ischemic attack.

Statistical significance.

Which Patients Exhibit a Significant Improvement in Renal Function After AF Ablation? {#jah34342-sec-0018}
-------------------------------------------------------------------------------------

We performed subgroup analyses to assess whether maintaining sinus rhythm after the last ablation procedure in some groups of patients helped improve 5‐year follow‐up eGFR. The analyses showed that the beneficial effect of maintaining sinus rhythm proved to be more prominent in patients with a CHA~2~DS~2~VASc score \<2, left atrial diameter \<45 mm, or left ventricular ejection fraction ≥50% and without preexisting comorbidities, including hypertension, diabetes mellitus, vascular disease, or advanced CKD (eGFR \<60 mL/min/1.73 m^2^; Figure [4](#jah34342-fig-0004){ref-type="fig"}). In particular, the positive effect of rhythm control on renal function improvement was more pronounced in patients without diabetes mellitus than in those with diabetes mellitus (*P* for interaction=0.012; Figure [4](#jah34342-fig-0004){ref-type="fig"}).

![Efficacy of the freedom form AF/AT recurrence after the last AFCA in subgroup analyses. AF indicates atrial fibrillation; AFCA,AF catheter ablation; ARB, angiotensin type II receptor blocker; AT, atrial tachyarrhythmia; BMI, body mass index; CHF, congestive heart failure; CKD, chronic kidney disease; DM, diabetes mellitus; E/Em, the ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity (Em); LA, left atrium, LVEF, left ventricular ejection fraction; OR, odds ratio; TIA,transient ischemic attack.](JAH3-8-e013204-g004){#jah34342-fig-0004}

Baseline Renal Function and Long‐Term Rhythm Outcome After AF Ablation {#jah34342-sec-0019}
----------------------------------------------------------------------

We compared advanced CKD (CKD stage ≥3; eGFR \<60 mL/min/1.73 m^2^) and early CKD (CKD stages 1 and 2; Table [5](#jah34342-tbl-0005){ref-type="table"}). Age, proportion with persistent AF at the de novo procedure, CHA~2~DS~2~VASc score, and proportion with a comorbid disease, including hypertension, diabetes mellitus, and vascular disease, and LA dimension, were significantly greater in AF patients with advanced CKD than in those with early CKD (Table [5](#jah34342-tbl-0005){ref-type="table"}). After adjusting for AF type during the de novo procedure, congestive heart failure, hypertension, diabetes mellitus, and a previous history of vascular disease, old age (adjusted OR, 1.11 \[1.07--1.15\]; *P*\<0.001) and baseline LA dimension (adjusted OR, 1.05 \[1.00--1.11\]; *P*=0.046) were independently associated with baseline advanced CKD (Table [S4](#jah34342-sup-0001){ref-type="supplementary-material"}). However, baseline CKD stage did not affect rhythm outcome of the AF catheter ablation after a single procedure (log rank, *P*=0.904) or after multiple procedures (log rank, *P*=0.381; Figure [S1](#jah34342-sup-0001){ref-type="supplementary-material"}).

###### 

Comparison of the Baseline Characteristics Among the Overall Patients With or Without Concomitant Advanced CKD

                             Advanced CKD   Early CKD     *P* Value
  -------------------------- -------------- ------------- ------------------------------------------------
  Age, y                     66.6±7.6       58.1±10.0     \<0.001[a](#jah34342-note-0011){ref-type="fn"}
  Male                       50 (74.6%)     363 (72.0%)   0.655
  PAF at procedure           37 (55.2%)     343 (68.1%)   0.036[a](#jah34342-note-0011){ref-type="fn"}
  Body mass index            25.2±2.7       24.9±2.9      0.318
  Body surface area          1.81±0.15      1.80±0.18     0.790
  CHA~2~DS~2~VASc score      2.8±1.6        1.7±1.5       \<0.001[a](#jah34342-note-0011){ref-type="fn"}
  Congestive heart failure   7 (10.4%)      23 (4.6%)     0.071
  Hypertension               50 (74.6%)     240 (47.6%)   \<0.001[a](#jah34342-note-0011){ref-type="fn"}
  Diabetes mellitus          22 (32.8%)     77 (15.3%)    \<0.001[a](#jah34342-note-0011){ref-type="fn"}
  Stroke/TIA                 10 (14.9%)     57 (11.3%)    0.388
  Vascular disease           17 (25.4%)     75 (14.9%)    0.028[a](#jah34342-note-0011){ref-type="fn"}
  LA dimension, mm           44.1±5.6       41.6±6.1      0.001[a](#jah34342-note-0011){ref-type="fn"}
  LVEF, %                    62.4±11.0      63.6±7.6      0.407
  E/Em                       11.6±4.4       10.5±5.1      0.099

CKD indicates chronic kidney disease; E/Em, the ratio of the early diastolic mitral inflow velocity (E) to the early diastolic mitral annular velocity (Em); LA, left atrium; LVEF, left ventricular ejection fraction; PAF, paroxysmal atrial fibrillation; TIA, transient ischemic attack.

Statistical significance.

Discussion {#jah34342-sec-0020}
==========

Major Findings {#jah34342-sec-0021}
--------------

In this study, we sought to determine how AF ablation contributed to long‐term renal function as compared with medical therapy alone by comparing an AF ablation cohort database and an NHIS database after retrospective propensity‐score matching. AF catheter ablation, but not medical therapy, significantly improved 5‐year follow‐up eGFR, and this improvement in long‐term renal function was more significant in patients who remained in sinus rhythm after the last AF ablation session and in those without preexisting diabetes mellitus. We also found that preexisting CKD was associated with degree of atrial structural remodeling before the catheter ablation, but did not affect the rhythm outcome of the AF catheter ablation.

AF and Renal Function {#jah34342-sec-0022}
---------------------

AF and CKD are both progressive degenerative diseases, and their prevalence increases with age. AF has been reported in ≈7% to 18% of CKD patients, and 12% to 25% of elderly individuals over 70 years of age with CKD have AF, which is 2 to 3 times that of the general population.[5](#jah34342-bib-0005){ref-type="ref"}, [23](#jah34342-bib-0023){ref-type="ref"}, [24](#jah34342-bib-0024){ref-type="ref"} In contrast, CKD is also associated with 10% to 15% of AF patients.[25](#jah34342-bib-0025){ref-type="ref"} Deterioration of renal function serves as an independent risk factor that increases AF prevalence, even in the early stages of CKD.[26](#jah34342-bib-0026){ref-type="ref"} It may be because of the mechanistic association between an impaired renal function and AF. Both AF and CKD have several common pathophysiologies, including neurohormonal activation of the renin‐angiotensin‐aldosterone system,[27](#jah34342-bib-0027){ref-type="ref"}, [28](#jah34342-bib-0028){ref-type="ref"}, [29](#jah34342-bib-0029){ref-type="ref"}, [30](#jah34342-bib-0030){ref-type="ref"} inflammatory factors,[31](#jah34342-bib-0031){ref-type="ref"}, [32](#jah34342-bib-0032){ref-type="ref"} and oxidative stress.[33](#jah34342-bib-0033){ref-type="ref"}, [34](#jah34342-bib-0034){ref-type="ref"}, [35](#jah34342-bib-0035){ref-type="ref"} Therefore, AF and renal dysfunction might adversely affect each other over time. In addition, CKD is important and clinically challenging in patients requiring anticoagulation, given that it simultaneously raises the thromboembolic and bleeding risks.[36](#jah34342-bib-0036){ref-type="ref"} However, given that CKD has a very heterogeneous nature[37](#jah34342-bib-0037){ref-type="ref"} and most major clinical trials related to AF management exclude advanced renal disease directly or indirectly,[38](#jah34342-bib-0038){ref-type="ref"} it is hard to define a comprehensive treatment policy for AF patients with CKD.

Renal Function and AF Catheter Ablation {#jah34342-sec-0023}
---------------------------------------

The irregular rhythm of AF reduces myocardial function[39](#jah34342-bib-0039){ref-type="ref"} and microvascular function,[40](#jah34342-bib-0040){ref-type="ref"} and a loss of atrial kick causes negative hemodynamic effects. Therefore, restoring sinus rhythm may improve renal function by changing the hemodynamics,[41](#jah34342-bib-0041){ref-type="ref"}, [42](#jah34342-bib-0042){ref-type="ref"}, [43](#jah34342-bib-0043){ref-type="ref"}, [44](#jah34342-bib-0044){ref-type="ref"} improving ventricular function,[16](#jah34342-bib-0016){ref-type="ref"} raising mean heart rate,[17](#jah34342-bib-0017){ref-type="ref"} and reducing inflammatory/oxidative reactions,[20](#jah34342-bib-0020){ref-type="ref"}, [33](#jah34342-bib-0033){ref-type="ref"}, [35](#jah34342-bib-0035){ref-type="ref"}, [45](#jah34342-bib-0045){ref-type="ref"} especially after catheter ablation. Although there have been multiple clinical studies that evaluated renal function after AF catheter ablation within 1 to 2 years of follow‐up,[15](#jah34342-bib-0015){ref-type="ref"}, [20](#jah34342-bib-0020){ref-type="ref"}, [21](#jah34342-bib-0021){ref-type="ref"}, [22](#jah34342-bib-0022){ref-type="ref"}, [46](#jah34342-bib-0046){ref-type="ref"} renal function is hard to determine because eGFR declines by 0.5 to 1 mL/min/1.73 m^2^ per year in the general population and 1 to 2.5 mL/min/1.73 m^2^ per year in patients with CKD.[47](#jah34342-bib-0047){ref-type="ref"} The present study included a longer‐term follow‐up of over 5 years in a higher number of patients, so we were able to more accurately evaluate the small differences in eGFR changes than in previous studies. We also conducted a consistent rhythm‐monitoring and follow‐up protocol based on the guidelines over 5 years.[19](#jah34342-bib-0019){ref-type="ref"} We found that aggressive rhythm control and a reduction in AF burden through repeat ablation sessions were associated with an improved renal function during the long‐term follow‐up period. However, such beneficial effects of strict rhythm control by AF ablation were not shown in patients with preexisting diabetes mellitus. It might be because diabetes mellitus is associated with LA fibrosis and electroanatomical LA remodeling, which result in impairment of the LA reservoir and pump function.[48](#jah34342-bib-0048){ref-type="ref"}, [49](#jah34342-bib-0049){ref-type="ref"} Diabetes mellitus is also a well‐known risk factor of CKD and progressive deterioration of renal function.[50](#jah34342-bib-0050){ref-type="ref"} These adverse effects on the heart and kidneys of diabetes mellitus appear to have little effect on long‐term renal function improvement, despite active AF rhythm control by AFCA.

Limitations {#jah34342-sec-0024}
-----------

This study had several limitations. It was an observational cohort study from a single center, so highly selected patients referred for AF were included in this study. Because we considered that there was an improvement in renal function in patients whose ΔeGFR~5 yrs~ was above 0 mL/min/1.73 m^2^, this study might not be able to represent an improvement in CKD stage. Because many of the patients who underwent AFCA did not have advanced CKD, this study might not be able to represent a broad spectrum of patients with an impaired renal function. We could not investigate the mechanism of the association between renal function improvement and maintenance of sinus rhythm by comparing the change in hemodynamics and inflammatory markers; however, it was not the main subject of this study.

Conclusions {#jah34342-sec-0025}
===========

AF catheter ablation significantly improved renal function during the 5‐year follow‐up. Reduction in AF burden, even with repeat ablation sessions, was independently associated with an improvement in renal function in patients without preexisting diabetes mellitus as well as in the overall patients. However, patients with preexisting diabetes mellitus had no beneficial improvement in renal function; however, sinus rhythm was maintained after repeat ablation sessions.
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**Table S1.** Logistic Regression Analysis for Variables Predicting an Improved Renal Function (ΔeGFR~5 yr~ ≥1) After 5 Years of Follow‐up (n=2284)

**Table S2.** Logistic Regression Analysis for Variables Predicting an Improved Renal Function (ΔeGFR~5 yr~ \>5) After 5 Years of Follow‐up (n=2284)

**Table S3.** Linear Regression Analysis for Variables Predicting a Change in eGFR (ΔeGFR~5 yr~) After 5 Years of Follow‐up (n=2284)

**Table S4.** Logistic Regression Analysis of the Baseline Risk Factors Predicting Advanced CKD Among the Overall Patients With AFCA (n=571)

**Figure S1.** Kaplan--Meier analysis of an AF/AT recurrence after a single AF ablation (**A**) and the last AF ablation (**B**) according to baseline advanced CKD.
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